BioMarin Pharmaceutical, Inc. (BMRN)
56.70
-1.63
(-2.79%)
USD |
NASDAQ |
Nov 12, 16:00
57.10
+0.40
(+0.71%)
After-Hours: 07:42
BioMarin Pharmaceutical Shareholders Equity (Quarterly) : 6.256B for Sept. 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 6.256B |
| June 30, 2026 | 6.322B |
| March 31, 2026 | 6.212B |
| December 31, 2025 | 6.087B |
| September 30, 2025 | 6.057B |
| June 30, 2025 | 6.027B |
| March 31, 2025 | 5.793B |
| December 31, 2024 | 5.658B |
| September 30, 2024 | 5.413B |
| June 30, 2024 | 5.286B |
| March 31, 2024 | 5.074B |
| December 31, 2023 | 4.952B |
| September 30, 2023 | 4.897B |
| June 30, 2023 | 4.783B |
| March 31, 2023 | 4.659B |
| December 31, 2022 | 4.603B |
| September 30, 2022 | 4.569B |
| June 30, 2022 | 4.505B |
| March 31, 2022 | 4.391B |
| December 31, 2021 | 4.271B |
| September 30, 2021 | 4.266B |
| June 30, 2021 | 4.242B |
| March 31, 2021 | 4.162B |
| December 31, 2020 | 4.106B |
| September 30, 2020 | 4.054B |
| Date | Value |
|---|---|
| June 30, 2020 | 3.237B |
| March 31, 2020 | 3.240B |
| December 31, 2019 | 3.122B |
| September 30, 2019 | 3.074B |
| June 30, 2019 | 2.961B |
| March 31, 2019 | 2.937B |
| December 31, 2018 | 2.968B |
| September 30, 2018 | 2.915B |
| June 30, 2018 | 2.885B |
| March 31, 2018 | 2.807B |
| December 31, 2017 | 2.809B |
| September 30, 2017 | 2.814B |
| June 30, 2017 | 2.796B |
| March 31, 2017 | 2.769B |
| December 31, 2016 | 2.766B |
| September 30, 2016 | 2.646B |
| June 30, 2016 | 1.918B |
| March 31, 2016 | 2.290B |
| December 31, 2015 | 2.401B |
| September 30, 2015 | 2.293B |
| June 30, 2015 | 2.357B |
| March 31, 2015 | 2.425B |
| December 31, 2014 | 1.528B |
| September 30, 2014 | 1.508B |
| June 30, 2014 | 1.462B |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Exelixis, Inc. | 1.834B |
| Ascendis Pharma A/S | -- |
| Alnylam Pharmaceuticals, Inc. | 3.604B |
| Anika Therapeutics, Inc. | 137.58M |
| Cytokinetics, Inc. | -321.17M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 11.57B |
| Total Liabilities (Quarterly) | 5.313B |
| Debt to Equity Ratio | 0.6723 |
| Current Ratio | 2.443 |
| Net Debt Paydown Yield | -6.19% |